Evidence map›Paper›PMID 41491850›Full record

ArticleThe AAPS journal2026

Investigation of Monoclonal Antibody Pharmacokinetics in Pediatric Population and Characterization Using a Platform PBPK Model.

Mokshada Kumar, Sravani Lanke, Dhaval K Shah

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mokshada Kumar *Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences,, The State University of New York at Buffalo, 455 Pharmacy Building, Buffalo, New York, 14214-8033, USA.
Sravani Lanke *Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences,, The State University of New York at Buffalo, 455 Pharmacy Building, Buffalo, New York, 14214-8033, USA.
Dhaval K ShahDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences,, The State University of New York at Buffalo, 455 Pharmacy Building, Buffalo, New York, 14214-8033, USA. dshah4@buffalo.edu.ORCID 0000-0002-0723-6206

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the impact of age on pediatric PK of mAbs and develop a platform PBPK model to support optimal dosing of mAbs in pediatric patients. After extensive literature review 49 mAbs were identified as approved for pediatric use, but only 17 had adequate PK data to support the investigation. It was found that pediatric patients exhibit 20-40% lower initial concentration (i.e. C

Indexed as

Antibodies, MonoclonalModels, BiologicalAdolescentAdultAge FactorsBody WeightChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleMetabolic Clearance RateAntibodies, Monoclonalchildrenmonoclonal antibodyontogenyPBPKpediatricspharmacokinetics

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.